RxDoctor Payments Data

Leigh Hutchinson, MD

Cardiology · Hauppauge, NYNPI 1568497204

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $6,845 of the $11,078 with a category attached, or 61.8%. 26 manufacturers reported payments, led by Medical Device Business Services, Inc. at 38.1% of the total. Reporting peaked in 2019 at $5,467 and has fallen 91.4% since, to $470 in 2025.

$11,078in general payments, 2019–2025

Across 222 payments — averaging $49.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$4K
  • Medtronic$3K
  • Novartis$736
  • Boston Scientific$706
  • Merck$685
  • Sanofi-aventis U.S. LLC$256
  • plus $2K from 20 others

What the payments were for

  • Travel & lodging$6,84562%
  • Food & beverage$4,15337%
  • Education$801%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,078 in reported general payments places this provider in the 85th percentile of 112 cardiology providers in New York.

See all cardiology providers in New York

Medicare billing

Part B allowed, 2024
$292,738
Medicare patients
2,246
Services billed
5,104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban38$48,170
EntrestoSacubitril/Valsartan17$33,902
EliquisApixaban22$27,995
Praluent PenAlirocumab22$11,561
Metoprolol Succinate167$2,476
Pindolol30$1,878
Clonidine25$1,742
Diltiazem 24hr Er (Cd)Diltiazem Hcl19$1,025
Chlorthalidone25$909
Ezetimibe25$526
Amiodarone Hcl24$442
Torsemide30$420
Hydralazine Hcl40$347
Clonidine Hcl33$331
Losartan Potassium40$321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$244$48,17038 claims
NovartisEntresto$736$33,90217 claims
PfizerEliquis$205$27,99522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 112 cardiology providers in New York.

Other cardiology in Hauppauge

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →